iBio (NASDAQ: IBIO) reported fiscal 2026 revenue of $0.1 million and a net loss of $33.0 million, or $0.32 per basic and diluted share, for the year ended June 30, 2026.
The clinical-stage biotechnology company said it advanced IBIO-600 through the single ascending dose portion of its Phase 1 trial and moved IBIO-610 into IND-enabling studies.
- Cash, cash equivalents and investments in debt securities totaled approximately $88.0 million as of June 30, 2026.
- R&D expense was $19.6 million, compared with $8.3 million in fiscal 2025.
- General and administrative expense was $10.6 million, compared with $10.7 million a year earlier.
- iBio recorded a $5.0 million impairment of its IBIO-101 indefinite-lived intangible asset.
- The company said its financings extended its cash runway into fiscal 2028.
$IBIO Insider Trading Activity
$IBIO insiders have traded $IBIO stock on the open market 4 times in the past 6 months. Of those trades, 4 have been purchases and 0 have been sales.
Here’s a breakdown of recent trading of $IBIO stock by insiders over the last 6 months:
- FELIPE DURAN (Chief Financial Officer) purchased 24,835 shares for an estimated $50,131
- MARTIN BRENNER (See Remarks) purchased 12,336 shares for an estimated $24,918
- MARC BANJAK (Chief Legal Officer) has made 2 purchases buying 13,934 shares for an estimated $23,055 and 0 sales.
To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API insider transaction endpoint.
$IBIO Hedge Fund Activity
We have seen 36 institutional investors add shares of $IBIO stock to their portfolio, and 29 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- CORMORANT ASSET MANAGEMENT, LP added 3,570,000 shares (+inf%) to their portfolio in Q2 2026, for an estimated $6,247,500
- SILVERARC CAPITAL MANAGEMENT, LLC added 3,294,490 shares (+1457.7%) to their portfolio in Q2 2026, for an estimated $5,765,357
- VESTAL POINT CAPITAL, LP added 2,600,000 shares (+inf%) to their portfolio in Q2 2026, for an estimated $4,550,000
- ENSIGN PEAK ADVISORS, INC added 1,832,457 shares (+inf%) to their portfolio in Q2 2026, for an estimated $3,206,799
- WOODLINE PARTNERS LP added 1,776,547 shares (+inf%) to their portfolio in Q2 2026, for an estimated $3,108,957
- ECOR1 CAPITAL, LLC removed 1,583,000 shares (-100.0%) from their portfolio in Q2 2026, for an estimated $2,770,250
- LOGOS GLOBAL MANAGEMENT LP removed 1,300,000 shares (-100.0%) from their portfolio in Q2 2026, for an estimated $2,275,000
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.
